

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


linkedin.com/company/szaboscandic in



Product Information

IP Receptor (human) Blocking Peptide

Catalog No. 10005519



Laboratory Procedures

This vial contains 200 µg of lyophilized peptide. For long term storage, we suggest that the IP receptor blocking peptide be stored as supplied at -20°C. It will be stable for at least two years. This blocking peptide can be used in conjunction with Cayman's IP Receptor (human) Polyclonal Antibody (Catalog No. 10005518) to block protein-antibody complex formation during immunochemical detection of the IP receptor.

Reconstitute the lyophilized peptide with 200 μl of PBS or distilled water. Store this peptide solution at -20°C. It will be stable for at least two years. To block antibody/protein complex formation, the following procedure is recommended:

- Mix the IP Receptor (human) Polyclonal Antibody (Catalog No. 10005518) and blocking peptide together in a 1:2 (v/v) ratio in a microfuge tube. For example, mix 20 μl of antibody and 40 μl of peptide.*
- Incubate for 1 hour at room temperature with occasional mixing prior to further dilution and application of the mixture to the immunoblot.
- 3. Dilute the mixture to the final working antibody concentration and apply to the slide or membrane as usual.

*This is a recommended mixture. The minimum amount of peptide needed for complete blocking has not been precisely determined and may vary depending on the sample being analyzed. The amount of peptide required may need to be increased if sufficient blocking does not occur.

References

- 1. Aristoff, P.A., Johnson, P.D., and Harrison, A.W. Synthesis of 9-substituted carbacyclin analogues. J. Org. Chem. 48, 5341-5348 (1983).
- Southall, M.D. and Vasko, M.R. Prostaglandin receptor subtypes, EP₃C and EP₄, mediate the prostaglandin E₂-induced cAMP production and sensitization of sensory neurons. J. Biol. Chem. 276(19), 16083-16091 (2001).
- Murata, T., Ushikubi, F., Matsuoka, T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678-682 (1997).
- Cheng, Y., Austin, S.C., Rocca, B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A₂. Science 296, 539-541 (2002).
- Cui, Y., Kataoka, Y., Satoh, T., et al. Protective effect of prostaglandin I2 analogs on ischemic delayed neuronal damage in gerbils. Biochem. Biophys. Res. Commun. 265, 301-304 (1999).
- McLaughlin, V.V., Genthner, D.E., Panella, M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 338, 273-277 (1998).
- Nakagawa, O., Tanaka, I., Usui, T., et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90, 1643-1647 (1994).
- Namba, T., Oida, H., Sugimoto, Y., et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J. Biol. Chem. 269, 9986-9992 (1994).
- Smyth, E.M., Nestor, P.V., and Fitzgerald, G.A. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J. Biol. Chem. 271(52), 33698-33704 (1996).

Related Product

IP Receptor (human) Polyclonal Antibody - Cat. No. 10005518

WARNING: THIS PRODUCT IS NOT INTENDED OR APPROVED FOR HUMAN OR VETERINARY USE. USE OF THIS PRODUCT FOR HUMAN OR ANIMAL TESTING IS EXTREMELY HAZARDOUS AND MAY RESULT IN DISEASE, SEVERE INJURY, OR DEATH.

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

ayman Chemical Company makes no warranty or guarantee of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular se, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications

the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a retinal of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that

does not meet our specifications.

Said refund or replacement is conditioned on Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 06/17/2010

Cayman Chemical

Mailing address

1180 E. Ellsworth Road Ann Arbor, MI 48108 USA

(800) 364-9897 (734) 971-3335

(734) 971-3640

custserv@caymanchem.com

www.caymanchem.com